Just then, the host received a note from backstage.

After looking at the note, he said to the camera, "I just received a piece of news. DS Pharmaceuticals has acquired the British company Pleasant Pharmaceuticals for $40 billion."

The host then turned to the expert and said, "Pleius is a renowned multinational pharmaceutical group. Its anti-cancer drugs are very well-known in the market. $40 billion is equivalent to over 40 trillion won. What do you think of this acquisition?"

"Where does the news come from?" the expert confirmed.

"According to AP News, DS Pharmaceuticals has acquired this British pharmaceutical company for $50 per share, a 15% increase from last weekend's share price. Pleasant's cancer drugs, painkillers, and depression medications are all very popular. This acquisition has transformed DS Pharmaceuticals into one of the world's leading pharmaceutical companies. It's truly astonishing."

"It's truly astonishing. DS Pharmaceuticals and Pleius aren't even on the same level. This is a classic case of a snake swallowing an elephant."

In the living room of the mansion, Han Ji-yeon asked Park Jin-hyuk in surprise, "Is this true?"

Park Jin Hyuk smiled and nodded. "We just signed the merger and acquisition agreement yesterday. I didn't expect it to go so smoothly."

In the market, after hearing that DS Pharmaceuticals was looking for suitable acquisition targets, some pharmaceutical companies took the initiative to contact DS Pharmaceuticals, because the ongoing Paris flu epidemic has put many pharmaceutical companies in operational difficulties.

But even so, such a large-scale merger and acquisition usually takes one year or even several years. One of the reasons why DS Pharmaceuticals was able to complete this acquisition so quickly is that Park Jin Hyuk has a keen eye for identifying corporate value.

"40 trillion won is not a small amount," said Han Ji-yeon.

"To be precise, it was 44 trillion won. DS Pharmaceuticals only paid 10 trillion won, and the rest was borrowed from banks."

Given DS Pharmaceuticals' current financial situation, it would be easy for it to obtain bank loans. Large international investment banks such as Goldman Sachs, JP Morgan, Bank of America, Citibank and Deutsche Bank have all extended olive branches to DS Pharmaceuticals.

*** *** ***

The beginning of the year is the time when companies hold shareholders' meetings. DS Pharmaceuticals is also holding a shareholders' meeting to report last year's operating performance and future plans to shareholders.

The host said, "Next, please allow Vice Chairman Park Jin Hyuk of DS Group to speak."

Amidst thunderous applause from shareholders, Park Jin Hyuk walked up to the podium.

"Thank you! It's only right that President Mao Dayong should be here to introduce DS Pharmaceutical's future plans. However, at your and President Mao's request, I'm here to speak. Over the past year, DS Pharmaceutical has achieved unprecedented leaps and bounds, with operating revenue increasing 20-fold, operating profit increasing 45-fold, and net profit increasing 30-fold."

The audience suddenly erupted in thunderous applause and cheers.

"DS Pharmaceuticals is expected to maintain this positive growth momentum over the next five years. Driven by this market expectation, DS Pharmaceuticals' stock price has increased 30-fold compared to the beginning of the year, making it one of the top three listed companies by market capitalization."

Applause and cheers rang out again from the audience, and after a few minutes people gradually quieted down.

"Not long ago, news broke that DS Pharmaceuticals was acquiring Pleasant Pharmaceuticals. I want to tell you..." Park Jin Hyuk paused, the 500-plus shareholders in the audience watching him intently, "DS Pharmaceuticals has indeed acquired the British company Pleasant Pharmaceuticals for $40 billion."

Park Jin Hyuk continued, "After the shareholders' meeting, we will distribute dividends based on last year's performance. 7% of the total market value on the dividend date will be distributed to shareholders..."

There was another round of applause from the audience. The 7% dividend ratio exceeded the usual standard.

"Also, I'm proposing to adjust the company's articles of association to change the annual year-end dividend to four quarterly dividends a year..."

Amid the cheers and applause of shareholders, Park Jin Hyuk finished his speech and walked down the podium.

After the shareholders' meeting ended, shareholders came forward to shake hands with Park Jin Hyuk and express their congratulations. Some shareholders even asked to take a photo with him.

Only after returning to Mao Dayong's office accompanied by his subordinates was Park Jin Hyuk able to sit down and rest.

"The shareholders' response was really enthusiastic," said Mao Dayong.

"Yeah." Park Jin Hyuk nodded, then asked Mao Dayong, "How's it going? Is the M&A project going smoothly?"

"Yes, all the procedures have been completed. Furthermore, we are constantly being contacted by companies hoping to discuss mergers and acquisitions. Furthermore, DS BioLogics has received the construction permit for its new factory."

"Very good." Park Jin Hyuk nodded.

At this time, Jin Junyu knocked on the door and walked in.

"Vice President, there's a call from Chengsheng."

"Sure enough, it called right after we finished the shareholders' meeting."

"Are you planning something with Chengsheng Group?" Mao Dayong asked.

Park Jin Hyuk stood up and said, "Yes, I am going to meet Chairman Choi of Sung Seung Group now and settle my sister's lifelong event."

He turned around and told Jin Junyu: "Tell Chairman Cui of Chengsheng to meet at Qingyi Pavilion where we met last time."

"Yes." Jin Junyu agreed and walked out.

Before leaving, Park Jin Hyuk told Mao Dayong, "President Mao, DS Pharmaceuticals can be more public about its work. This will also be helpful to me in discussing things."

"Yes, I understand."

*** *** ***

When Park Jin Hyuk arrived at Qingyi Pavilion, Chairman Han Jung-hwan's wife, Ms. Jin, and Ms. Zheng were already waiting for him at the door.

"Long time no see." Ms. Jin walked quickly forward and shook Park Jin Hyuk's hand, appearing extremely enthusiastic. "I heard everything you said to my sister last time." As she spoke, she glanced at Ms. Zheng.

Then, they accompanied Park Jin Hyuk to the private room and sat down.

Ms. Jin continued, "We've had a lawyer review the previous equity entrustment documents, and there's no problem. It would be great if you could take care of our son in the future."

She glanced at Ms. Zheng and continued, "Have you met my eldest son? He's very smart. My second son is still in high school and is also doing well in his studies. Please take good care of him in the future."

"How did you know?" Park Jin Hyuk asked slowly.

Looking at Park Jin Hyuk with a serious face, Ms. Jin was stunned for a moment.

Park Jin Hyuk asked Ms. Zheng, "Did you tell her?"

"Well, I was just saying it casually..."

Ms. Jin interrupted again, "Son-in-law, I don't know what she thinks, but I'm very willing to cooperate with you."